Patient Characteristics
| Characteristic | Data |
|---|---|
| Sex | |
| Female | 6 |
| Male | 14 |
| 68Ga-DOTATATE-identified bone lesions | |
| Yes | 8 |
| No | 12 |
| Age (y) | 66 (48–76) |
| Patients with blood values between treatment fractions | 20* |
| Patients with blood values at 3-mo follow-up | 19† |
| Patients with blood values at 6-mo follow-up | 14 |
| Previous chemotherapy‡ | 0 (0–4) |
↵* One patient was missing platelets.
↵† Two patients were missing absolute neutrophil count.
↵‡ Four patients had previously received capecitabine plus temozolomide and everolimus; 2 patients, capecitabine plus temozolomide; 2 patients, everolimus; 1 patient, 2 cycles of PRRT; 1 patient, capecitabine plus temozolomide plus etoposide; and 1 patient, capecitabine plus temozolomide, everolimus, sunitinib, and temozolomide.
Qualitative data are number; continuous data are median and range.